Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients
Latest Information Update: 06 May 2022
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms ETHIC
- 26 Apr 2022 Status changed from recruiting to discontinued. Reason the study was stopped:Average event rate (end point) was much lower than expected. A larger sample size would havebeen required to maintain same statistical power, which was not achievable in a feasible timescale. No safety concerns were identified with bleeding.
- 14 Apr 2022 This trial has been discontinued in Germany according to European Clinical Trials Database record.
- 13 Apr 2021 Planned End Date changed from 1 Jul 2021 to 1 Sep 2021.